A cheap and widely available steroid, dexamethasone can help save the lives of patients seriously ill with coronavirus
Researchers led by Professor Peter Horby at the University of Oxford, in England say they have the first evidence that
Category: Pharma applications
Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
In a pandemic like Covid-19 the urgent need excludes the development of new drugs, “conventional drug in new use” becomes
Eva Pharma, DRL, Biocon and Zydus Cadila added to Voluntary Licensing Agreements for Remdesivir
Gilead has signed non-exclusive voluntary licensing agreements with further generic pharmaceutical manufacturers based in Egypt and India to further expand supply
Conditional approval of Veklury® (SBECD-enabled remdesivir) for COVID-19 infection in Singapore
The Health Sciences Authority (HSA), in consultation with its Medicines Advisory Committee and infectious diseases experts informed healthcare professionals on
Vaccines against COVID-19
Vaccines against COVID-19 will hopefully give broad parts of the human population a safe level of immunity and are considered
Can Estrogen and Other Sex Hormones Help Men Survive Covid-19?
The gender gap in coronavirus survival became apparent early in the pandemic. Reports from China indicated men were dying at
ALL EYES ON GILEAD
Bloombergs Businessweek published the story on how Gilead scineces prepared for the recently obtained emergency approval of the antiviral drug
Takeda Announces Data from the Phase 2 Trial of SBECD-enabled Pevonedistat Plus Azacitidine
Takeda Pharmaceutical Company Limited announced the results of the Phase 2 Pevonedistat-2001 trial. The study evaluated a cyclodextrin-enabled (SBECD) pevonedistat plus
Ligand CEO Issues Letter to Captisol Customers
Yesterday, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers. The
Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19
Gilead Sciences, Inc. announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This